EW Stock Down -5.1% after 8-Day Loss Streak
Edwards Lifesciences (EW) stock hit day 8 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -5.1% return. The company has lost about $2.3 Bil in value over the last 8 days, with its current market capitalization at about $46 Bil. The stock remains 4.8% above its value at the end of 2024. This compares with year-to-date returns of 11.9% for the S&P 500.
EW provides structural heart disease products, critical care, and surgical monitoring technologies, including aortic surgical valves, distributed via direct sales and independent distributors. Is this drop a warning sign or a setup for rebound? Deep dive with Buy or Sell EW.
Comparing EW Stock Returns With The S&P 500
The following table summarizes the return for EW stock vs. the S&P 500 index over different periods, including the current streak:
- General Mills Stock Delivers Strong Cash Yield – Upside Ahead?
- Stronger Bet Than Delta Air Lines Stock: LTM Delivers More
- CP Looks Smarter Buy Than Norfolk Southern Stock
- Pay Less, Gain More: MU, NVDA Top Monolithic Power Systems Stock
- Stronger Bet Than Cadence Design Systems Stock: APP Delivers More
- Pay Less, Gain More: CP Tops CSX Stock
| Return Period | EW | S&P 500 |
|---|---|---|
| 1D | -0.6% | -0.0% |
| 8D (Current Streak) | -5.1% | 2.6% |
| 1M (21D) | -0.1% | 1.8% |
| 3M (63D) | 2.2% | 8.9% |
| YTD 2025 | 4.8% | 11.9% |
| 2024 | -2.9% | 23.3% |
| 2023 | 2.2% | 24.2% |
| 2022 | -42.4% | -19.4% |
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact. Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: EW Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 49 S&P constituents with 3 days or more of consecutive gains and 22 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 20 | 7 |
| 4D | 21 | 8 |
| 5D | 2 | 4 |
| 6D | 0 | 0 |
| 7D or more | 6 | 3 |
| Total >=3 D | 49 | 22 |
Key Financials for Edwards Lifesciences (EW)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $5.0 Bil | $5.4 Bil |
| Operating Income | $1.5 Bil | $1.5 Bil |
| Net Income | $1.4 Bil | $4.2 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $1.4 Bil | $1.5 Bil |
| Operating Income | $409.9 Mil | $430.9 Mil |
| Net Income | $358.0 Mil | $329.8 Mil |
The losing streak EW stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.